Most importantly, preclinical studies indicate that the attenuation of CCDC6 in lung, pleural, prostate and bladder cancer determines cells sensitivity to inhibitors of PARP1/2 enzymes [19], [20], [21], [22]. This evidence concerns the gene CCDC6 and urinary bladder carcinoma.